The Current Role of Immunotherapy for Renal Cell Carcinoma in the Era of Targeted Therapeutics

被引：4

作者：

Wong, Michael K. K. ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Rochester, NY 14623 USA

来源：

CURRENT ONCOLOGY REPORTS | 2008年 / 10卷 / 03期

关键词：

D O I：

10.1007/s11912-008-0039-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The migration from cytokine therapy to the use of recently approved tyrosine kinase inhibitors and targeted therapeutic strategies may deprive some patients of a chance for long-term survival, as many clinicians now see these new agents as "easy fixes" for treating renal cell carcinoma (RCC). New developments pertaining to the mechanism, patient selection, predictive biomarkers, and administration of interleukin-2 mandate a reassessment of the clinical landscape and the clinical trial information upon which our current practices are based. Recalibration of the scales that we use to weigh the various possible therapies for advanced kidney cancer is also needed. Despite the shift away from cytokine therapy in the current treatment paradigm, new therapeutic approaches continue to build upon the undisputed fact that RCC can be cured with immunotherapy.

引用

页码：259 / 263

页数：5

共 21 条

[1]

[Anonymous], 2008, SUT SUN PACK INS

[2] Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].

Atkins, M ;

Regan, M ;

McDermott, D ;

Mier, J ;

Stanbridge, E ;

Youmans, A ;

Febbo, P ;

Upton, M ;

Lechpammer, M ;

Signoretti, S .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721

[3] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[4]

Bui MHT, 2003, CLIN CANCER RES, V9, P802

[5] RETRACTED: Immunotherapy for advanced renal cell cancer - art. no. CD001425.pub2 (Retracted Article) [J].

Coppin, C ;

Porzsolt, F ;

Awa, A ;

Kumpf, J ;

Coldman, A ;

Wilt, T .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01)

[6] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].

Dudley, ME ;

Wunderlich, JR ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Restifo, NP ;

Royal, RE ;

Kammula, U ;

White, DE ;

Mavroukakis, SA ;

Rogers, LJ ;

Gracia, GJ ;

Jones, SA ;

Mangiameli, DP ;

Pelletier, MM ;

Gea-Banacloche, J ;

Robinson, MR ;

Berman, DM ;

Filie, AC ;

Abati, A ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357

[7] Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma [J].

Escudier, Bernard ;

Lassau, Nathalie ;

Angevin, Eric ;

Soria, Jean Charles ;

Chami, Linda ;

Lamuraglia, Michele ;

Zafarana, Eric ;

Landreau, Veronique ;

Schwartz, Brian ;

Brendel, Eric ;

Armand, Jean-Pierre ;

Robert, Caroline .

CLINICAL CANCER RESEARCH, 2007, 13 (06) :1801-1809

[8] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9]

Figlin RA, 1997, CANCER J SCI AM, V3, pS68

[10]

Fisher RI, 2000, CANCER J SCI AM, V6, pS55

← 1 2 3 →